Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618436 · ClinicalTrials.gov registry record · Phase 4
Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT00618436 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 52 participants.
The verdict
NCT00618436, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
To show that the use of intravenous levetiracetam(LEV;Keppra)for seizure prevention in patients in the Neuroscience Intensive Care Unit will result in fewer side effects compared to the current standard of care anticonvulsant and will be at least as effective as the current standard of care in preventing clinical and sub-clinical seizure activity.
Interventions
- DRUG Levetiracetam
- DRUG Phenytoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618436
The ClinicalTrials.gov registry entry for NCT00618436 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levetiracetam is the first listed.
NCT00618436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618436 about?
NCT00618436 is a clinical study titled "Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention". To show that the use of intravenous levetiracetam(LEV;Keppra)for seizure prevention in patients in the Neuroscience Intensive Care Unit will result in fewer side effects compared to the current standard of care anticonvulsant and will be at least as effective as the current standard of care in preve...
What is the current status of trial NCT00618436?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2007-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00618436?
The interventions under investigation include: Levetiracetam (DRUG), Phenytoin (DRUG).
Who is sponsoring clinical trial NCT00618436?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.